All In MedTech

FDA Clearance Tracker · P030030-S003

BARD TEGRESS URETHRAL IMPLANT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 23, 2006 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 23, 2006

Approved

Time to decision

267 days

Received Aug 29, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P030030-S003
Device name
BARD TEGRESS URETHRAL IMPLANT
Applicant location
Covington, GA
Received
Aug 29, 2005
Decided
May 23, 2006
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P030030

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFICATIONS TO THE POSTAPPROVAL STUDY PROTOCOL.

Source documents

Other decisions for C.R. Bard, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.